This is a working overview of prothymosin alpha, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-04. Anything still debated is marked as such rather than presented as settled.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
== Test for alcohol consumption == Carbohydrate-deficient transferrin is elevated in the blood of people with heavy alcohol consumption but elevated levels can also be found in a number of medical conditions. The limitations of the assay depend upon the methodology of the test. HPLC (High Performance Liquid Chromatography) can detect certain genetic variants and potential liver diseases affecting CDT. Used with other tests, such as gamma glutamyl transferase (GGT), aspartate aminotransferase (AST), and alanine aminotransferase (ALT), carbohydrate-deficient transferrin can be a useful tool in identifying problem drinking, such as alcohol use disorder. However, it is less sensitive than phosphatidylethanol (PEth) in detecting current regular alcohol consumption. The ethanol conjugates called ethyl glucuronide and ethyl sulfate remain detectable for up to three days after ethanol consumption and are quite useful for detection of occult/denied alcohol use disorder. Both these substances are detectable clinically through urine drug testing by commercial toxicology labs. CDT is measured by taking a sample of a patient's blood. Apparently healthy individuals with no or low reported alcohol consumption and a negative Alcohol Use Disorders Identification Test (AUDIT) will have a %CDT <1.7% (95th percentile for the social drinking population). Elevated levels of CDT suggest recent heavy alcohol consumption, especially if other liver-associated enzymes (such as GGT) are elevated.
=== Chemical fingerprinting and breath analysis === The exhaled human breath contains a few thousand volatile organic compounds and is used in breath biopsy and is used in breath biopsy as a biomarker to test for diseases, such as lung cancer. One study has shown that "volatile organic compounds ... are mainly blood borne and therefore enable monitoring of different processes in the body." And it appears that VOC compounds in the body "may be either produced by metabolic processes or inhaled/absorbed from exogenous sources" such as environmental tobacco smoke. Chemical fingerprinting and breath analysis of volatile organic compounds has also been demonstrated with chemical sensor arrays, which utilize pattern recognition for detection of component volatile organics in complex mixtures such as breath gas.
== Products == Products of the first turn of the cycle are one GTP (or ATP), three NADH, one FADH2 and two CO2. Because two acetyl-CoA molecules are produced from each glucose molecule, two cycles are required per glucose molecule. Therefore, at the end of two cycles, the products are: two GTP, six NADH, two FADH2, and four CO2.
== Dedicated software == Ion mobility mass spectrometry is a rather recently popularized gas phase ion analysis technique. As such there is not a large software offering to display and analyze ion mobility mass spectrometric data, apart from the software packages that are shipped along with the instruments. ProteoWizard, OpenMS, and msXpertSuite are free software according to the OpenSourceInitiative definition. While ProteoWizard and OpenMS have features to allow spectrum scrutiny, those software packages do not provide combination features. In contrast, msXpertSuite features the ability to combine spectra according to various criteria: retention time, m/z range, drift time range, for example. msXpertSuite thus more closely mimics the software that usually comes bundled with the mass spectrometer.
Sources: en.wikipedia.org
=== Adverse effects === There may be side effects when changing over from glucose metabolism to fat metabolism. These may include headache, fatigue, dizziness, insomnia, difficulty in exercise tolerance, constipation, and nausea, especially in the first days and weeks after starting a ketogenic diet. Breath may develop a sweet, fruity flavor via production of acetone that is exhaled because of its high volatility. Most adverse effects of long-term ketosis are reported among children because of its longstanding acceptance as a treatment for pediatric epilepsy. These include compromised bone health, stunted growth, hyperlipidemia, and kidney stones.
There are also many overseas British independent schools in Hong Kong, such as Harrow International School Hong Kong, where 94% of students received grade (A*-B), Wycombe Abbey School Hong Kong, Malvern College Hong Kong, and Shrewsbury International School Hong Kong. Moreover, many schools cover various regions of the world, such as Australian International School, American International School, Canadian International School, French International School, and Korean International School among others. Local schools in Hong Kong are categorized into three "bands" based on academic performance, with Band 1 schools being the most prestigious and competitive. These institutions are often criticized for being high-pressure environments. Band 1 schools include Diocesan Boys' School, Diocesan Girls' School, Ying Wa College, St. Paul's College and La Salle College.
==== Luspatercept ==== Luspatercept is a drug used to treat anemia in adults with β-thalassemia, it can improve the maturation of red blood cells and reduce the need for frequent blood transfusions. It is administered by injection every three weeks. Luspatercept was authorised for use in the US in 2019 and by the European Medicines Agency in 2020.
== History == During the Soyuz 6 mission of 1969, Russian cosmonauts performed the first welding experiments in space. Three different welding processes were tested using a hardware unit called Vulkan. The tests included welding aluminum, titanium, and stainless steel. The Skylab mission, launched in May 1973, served as a laboratory to perform various space manufacturing experiments. The station was equipped with a materials processing facility that included a multi-purpose electric furnace, a crystal growth chamber, and an electron beam gun. Among the experiments to be performed was research on molten metal processing; photographing the behavior of ignited materials in zero-gravity; crystal growth; processing of immiscible alloys; brazing of stainless steel tubes, electron beam welding, and the formation of spheres from molten metal. The crew spent a total of 32 man-hours on materials science and space manufacturing investigation during the mission. The Space Studies Institute began hosting a bi-annual Space Manufacturing Conference in 1977 . Microgravity research in materials processing continued in 1983 using the Spacelab facility. This module has been carried into orbit 26 times aboard the Space Shuttle, as of 2002. In this role the shuttle served as an interim, short-duration research platform before the completion of the International Space Station.
== Virginia House of Delegates == In 2005, Wittman was elected to the Virginia House of Delegates, representing the 99th district. He served on the Agricultural; Chesapeake and Natural Resources; and Police and Public Safety Committees.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
Reconstituted solutions are typically kept refrigerated at two to eight degrees Celsius when used within a short window, or frozen in aliquots for longer periods. Repeated freeze-thaw cycles are avoided because they can reduce recovery of intact peptide.